8,000
Participants
Start Date
February 1, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
HPV vaccine
Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
HPV testing
HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
HAV vaccine
Hepatitis A virus (HAV) vaccine to be offered as a placebo
University of New Mexico
OTHER
University of Stellenbosch
OTHER
University of KwaZulu
OTHER
Coptic Hope Center
UNKNOWN
Emory University
OTHER
Ministry of Health, Swaziland
OTHER_GOV
Baylor College of Medicine Children's Foundation
UNKNOWN
Sefako Makgatho Health Sciences University
OTHER
Aga Khan University
OTHER
World Health Organization
OTHER
International Agency for Research on Cancer
OTHER